New insights into rifamycin B biosynthesis: isolation of proansamycin B and 34a-deoxy-rifamycin W as early macrocyclic intermediates indicating two separated biosynthetic pathways

J Antibiot (Tokyo). 2002 Apr;55(4):396-406. doi: 10.7164/antibiotics.55.396.

Abstract

Proansamycin B, the formerly postulated intermediate of rifamycin B biosynthesis, was isolated from cultures of the Amycolatopsis mediterranei mutant F1/24. The structure was determined using UV, IR, NMR and MS techniques. Biotransformation studies demonstrate that proansamycin B is an intermediate of a shunt pathway, a 8-deoxy variant, of rifamycin B biosynthesis leading to 8-deoxy-rifamycin B as the final product. In addition, 34a-deoxy-rifamycin W, the direct precursor of rifamycin W, could be isolated representing the earliest macrocyclic intermediate obtained so far in the biosynthetic route to rifamycin B. Furthermore, the new rifamycin W-28-desmethyl-28-carboxy and rifamycin W-hemiacetal, intermediates in the transformation sequence of rifamycin W to rifamycin S, were isolated. Application of proton NMR measurements (double resonance and ROESY experiments) on the latter compound indicated that the stereochemistry at the chiral center C-28 is R.

MeSH terms

  • Actinomycetales / genetics
  • Actinomycetales / growth & development
  • Actinomycetales / metabolism*
  • Anti-Bacterial Agents / biosynthesis*
  • Anti-Bacterial Agents / chemistry
  • Anti-Bacterial Agents / isolation & purification
  • Chromatography, High Pressure Liquid
  • Chromatography, Thin Layer
  • Magnetic Resonance Spectroscopy
  • Molecular Structure
  • Rifamycins / biosynthesis*
  • Rifamycins / chemistry
  • Rifamycins / isolation & purification*
  • Spectrophotometry, Ultraviolet

Substances

  • Anti-Bacterial Agents
  • Rifamycins
  • proansamycin B
  • rifamycin B